CMMB · Chemomab Therapeutics Ltd.

The American Depositary Shares reported in this row consist of restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on November 18, 2024, and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028.

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on July 1, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029.

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

These options shall vest and become exercisable in full at the end of the 12 month period commencing on June 16, 2023 subject to the Reporting Person's continued service.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Options granted under the Company's 2017 Equity-Based Incentive Plan (the "Plan") on June 14, 2023; 25% of the options vest and become exercisable following 12 months from the grant thereof and an additional 6.25% vests at the end of each calendar quarter thereafter such that the options are fully vested and exercisable on June 14, 2027, subject to acceleration upon a change in control pursuant to the terms of the Option Agreement ("CIC") by and between the Reporting Person and the Issuer and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan).

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

These options vest and become exercisable in equal monthly installments over a 36 month period, subject to the Reporting Person's continued service.

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service. These options were granted as per the annual grant of options to directors.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.

These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

These options were granted as per the annual grant of options to directors. Those options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Each American Depository Share ("ADS") represents 20 Ordinary Shares of the Issuer.

Represents the weighted average sale price of the ADSs sold, ranging from a low of $3.87 to a high of $4.83 per ADS. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of ADSs sold at each separate price.

These ADSs are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the ADSs held directly by OIP and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP.

This report is being jointly filed by OrbiMed BioFund and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

This transaction was effected pursuant to a 10b5-1 plan entered into on September 19, 2022.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

This transaction was effected pursuant to a 10b5-1 plan entered into on September 19, 2022.

Each American Depository Share ("ADS") represents 20 Ordinary Shares of the Issuer.

Represents the weighted average sale price of the ADSs sold, ranging from a low of $2.85 to a high of $3.81 per ADS. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of ADSs sold at each separate price.

These ADSs are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the ADSs held directly by OIP and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP.

This report is being jointly filed by OrbiMed BioFund and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

The ADSs are held of record directly by the Phoenix Insurance Company Ltd. (Naftali Neil Cohen) (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.

Based upon the 12,409 ADSs previously held as reported by Mr. Neil Cohen on Form 4 filed with the SEC on May 19, 2022.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

The reported price in Column 4 is a weighted average price pursuant to the share purchase agreement between Adi Mor, Kobi George, and the Issuer, as disclosed in the Issuer's Form 8-K filed with the Securities and Exchange Commission on November 16, 2022.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

The reported price in Column 4 is a weighted average price pursuant to the share purchase agreement between Adi Mor, Kobi George, and the Issuer, as disclosed in the Issuer's Form 8-K filed with the Securities and Exchange Commission on November 16, 2022.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this form 4 for informational purposes only.

These options vest and become exercisable pursuant to the following schedule: 25% of the options shall vest on November 8, 2023, and the remainder shall vest over three years in quarterly equal installments, subject to acceleration upon a change in control ("CIC") and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan).

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this form 4 for informational purposes only.

These options vest and become exercisable in equal monthly installments over a 36 month period commencing on June 16, 2022, subject to the Reporting Person's continued service.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Includes the previously reported 1,000 ADSs of the Company, as reported by Mr. Joel Maryles on Form 4 filed with the SEC on March 21, 2022.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Includes the previously reported 1,000 ADSs of the Company, as reported by Mr. Joel Maryles on Form 4 filed with the SEC on March 21, 2022.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

The ADSs are held of record directly by the Phoenix Insurance Company Ltd. (Naftali Neil Cohen) (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.

Includes the previously reported 10,409 ADSs of the Company, as reported by Mr. Neil Cohen on Form 4 filed with the SEC on March 15, 2022.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

The ADSs are held of record directly by the Phoenix Insurance Company Ltd. (Naftali Neil Cohen) (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

The ADSs are held of record directly by the Phoenix Insurance Company Ltd. (Naftali Neil Cohen) (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

The ADSs are held of record directly by the Phoenix Insurance Company Ltd. (Naftali Neil Cohen) (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

The ADSs are held of record directly by the Ashdanit Medical Ltd. (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole ultimate beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.

These options vest and become exercisable in their entirety on March 16, 2023.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

These options vest and become exercisable in their entirety on March 16, 2023.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

These options vest and become exercisable in their entirety on March 16, 2023, subject to the Reporting Person's continued service.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

These options vest and become exercisable in their entirety on March 16, 2023.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

These options vest and become exercisable in their entirety on March 16, 2023.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

These options vest and become exercisable in their entirety on March 16, 2023.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

These options vest and become exercisable in their entirety on March 16, 2023.

Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.